Edition:
India

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

137.11USD
1:30am IST
Change (% chg)

$-0.08 (-0.06%)
Prev Close
$137.19
Open
$136.48
Day's High
$137.54
Day's Low
$134.83
Volume
2,518,749
Avg. Vol
1,967,266
52-wk High
$157.00
52-wk Low
$109.17

Select another date:

Fri, Oct 30 2020

Photo

J&J plans to test its COVID-19 vaccine in ages 12-18 soon

NEW YORK Johnson & Johnson plans to start testing its experimental COVID-19 vaccine in youths aged 12 to 18 as soon as possible, a company executive said at a meeting held by the U.S. Centers for Disease Control and Prevention (CDC) on Friday.

J&J plans to test its COVID-19 vaccine in ages 12-18 soon

NEW YORK Johnson & Johnson plans to start testing its experimental COVID-19 vaccine in youths aged 12 to 18 as soon as possible, a company executive said at a meeting held by the U.S. Centers for Disease Control and Prevention (CDC) on Friday.

UPDATE 1-J&J plans to test its COVID-19 vaccine in ages 12-18 soon

NEW YORK, Oct 30 Johnson & Johnson plans to start testing its experimental COVID-19 vaccine in youths aged 12 to 18 as soon as possible, a company executive said at a meeting held by the U.S. Centers for Disease Control and Prevention (CDC) on Friday.

J&J plans test of its COVID-19 vaccine candidate in 12-18 year olds soon

NEW YORK, Oct 30 Johnson & Johnson plans to start testing its COVID-19 vaccine candidate in 12 to 18 year olds as soon as possible, a company executive said at a meeting held by the U.S. Centers for Disease Control and Prevention on Friday.

EU Commission says talking to four companies on COVID vaccine

BRUSSELS, Oct 29 The European Commission is in talks with four companies to secure a potential COVID-19 vaccine, President Ursula von der Leyen said on Thursday following an EU leaders' video conference.

FACTBOX- The race for a coronavirus vaccine

(Adds Vaxart, updates AstraZeneca, Moderna, J&J, Bharat Biotech, Russia's vaccine) Oct 29 Pfizer and German partner BioNTech, along with Moderna and AstraZeneca, are at the forefront in the race to successfully develop a safe and effective COVID-19 vaccine. There are 45 vaccine candidates in human trials worldwide, with those from Pfizer and Moderna with a chance to get regulatory nod before the end of the year. The following table tracks the latest developments from major

AstraZeneca resumes U.S. COVID-19 vaccine trial and next week J&J prepares to do same

AstraZeneca Plc has resumed the U.S. trial of its experimental COVID-19 vaccine after approval by regulators, and Johnson & Johnson is preparing to resume its trial on Monday or Tuesday, the companies said on Friday. | Video

AstraZeneca resumes U.S. COVID-19 vaccine trial and next week J&J prepares to do same

AstraZeneca Plc has resumed the U.S. trial of its experimental COVID-19 vaccine after approval by regulators, and Johnson & Johnson is preparing to resume its trial on Monday or Tuesday, the companies said on Friday. | Video

AstraZeneca resumes U.S. COVID-19 vaccine trial and next week J&J prepares to do same

AstraZeneca Plc has resumed the U.S. trial of its experimental COVID-19 vaccine after approval by regulators, and Johnson & Johnson is preparing to resume its trial on Monday or Tuesday, the companies said on Friday. | Video

WRAPUP 8-AstraZeneca resumes U.S. COVID-19 vaccine trial and next week J&J prepares to do same

Oct 23 AstraZeneca Plc has resumed the U.S. trial of its experimental COVID-19 vaccine after approval by regulators, and Johnson & Johnson is preparing to resume its trial on Monday or Tuesday, the companies said on Friday.

Select another date: